Key Drivers
- Strong cash cushion
- Minimal leverage
- Persistent cash burn
AIAI Summary
BioAge has shifted from a pure early-stage biology bet to a finance-driven, event-dependent investment where credible biomarker wins for BGE-102 and oral retinal exposure create meaningful upside potential, but the upsized $115M equity raise, insider selling, and rising short interest make downside asymmetric until replicated Phase‑2 readouts and clear post-close runway visibility; monitor 1H‑2026 BGE‑102 data and net cash/burn projections as the decisive catalysts.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong cash cushion
- •Minimal leverage
- •Persistent cash burn
BIOA has a very strong liquidity and low-leverage profile (large cash balance vs. minimal debt) but faces persistent operating losses and negative cash flow driving a rapid cash drawdown and execution risk.
Price Behavior
Key Price Behavior Insights:
- •Below SMA
- •Range-bound trading
- •Support-tested rebounds
Price is in a modest short-term downtrend—down ~6% over the last month, trading below its last-month SMA and stuck in a $18.7–$22.3 range implying risk to the downside if $18.72 fails.
Price declined from $20.51 to $19.30 (≈6%) over the last month indicating short-term weakness
Sentiment & News
Key News Insights:
- •47.6% increase
- •1.34M shares
- •644k avg volume
Short interest in BioAge jumped 47.6% to 1,341,664 shares by Feb 13, 2026, indicating growing bearish positioning amid average daily volume of 644,382.
Rising short interest raises downside pressure and volatility for BioAge, increasing risk of further declines or a short squeeze if catalysts emerge
Similar Companies in Healthcare
Other companies in the same sector with AI ratings